Showing results (61-70 of 92) with videos related to
Sort By:
Pageof 10
Leukemia|July 6, 2007
Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlationA Rodríguez, R Villuendas, L Yáñez, et al.The Journal of Dermatological Treatment|November 4, 2017
Redefining the therapeutic objective in psoriatic patients candidates for biological therapyG Carretero, L Puig, J M Carrascosa, et al.Actas Dermo-Sifiliograficas|July 5, 2015
Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over timeJ M Carrascosa, N Rivera, I Garcia-Doval, et al.Clinical and Experimental Dermatology|August 26, 2020
Capillary malformation-arteriovenous malformation syndrome: a multicentre studyM Valdivielso-Ramos, A Martin-Santiago, J M Azaña, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|April 2, 2014
Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registryG Carretero, C Ferrandiz, E Dauden, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|September 5, 2014
Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registryC Medina, G Carretero, C Ferrandiz, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|June 23, 2016
Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysisP Dávila-Seijo, E Dauden, G Carretero, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|March 3, 2017
Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registryA Pérez-Plaza, G Carretero, C Ferrandiz, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|May 10, 2017
Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, BiobadadermI Belinchón, J M Ramos, G Carretero, et al.Actas Dermo-Sifiliograficas|April 17, 2025
Genetic Polymorphisms in Psoriasis: Investigating Genetic Variations for Precise Profiling of Response to Brodalumab in Real-Life Clinical PracticeB Butrón-Bris, M Llamas-Velasco, S Armesto, et al.Pageof 10